Sexcord/ stromal ovarian tumors overview: Difference between revisions
| (25 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}};{{M.N}} | {{CMG}}; {{AE}};{{M.N}} | ||
==Overview== | ==Overview== | ||
[[Ovarian]] sex cord-stromal tumors are a diverse group of both [[benign]] and [[malignant]] [[neoplasms]] that develop from the dividing [[cell]] population which would normally give rise to [[cells]] that surrounds the [[oocytes]], including the [[cells]] that produce [[ovarian hormones]] (the nongerm cell and nonepithelial components of the [[gonads]]).The [[Year|yearly]] adjusted [[incidence rate]] is approximately 2 per 1,000,000 [[women]] for sexcord-stromal ovarian tumors(SCSTs). The [[mortality rate]] has gradually been declining from1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. The [[age]] at presentation varies depending on the subtypes of sexcord-stromal ovarian tumors. Sexcord-stromal ovarian tumors(SCSTs) have more predilection in [[women]] of Caucasian background. Rates are highest among Whites, intermediate for Hispanics, and lowest among Blacks, and Asian people. Sexcord/ stromal ovarian tumors may be classified according to [[WHO]] into 3 subtypes: Pure stromal tumors, pure sexcord tumors, mixed stromal and sexcord tumors. [[Histological]] [[classification]] of sexcord-stromal ovarian tumors includes [[granulosa]] stromal cell tumors, [[Sertoli-Leydig cell tumour|sertoli leydig cell tumors]], gynandroblastoma, and unclassified. The exact [[pathogenesis]] of sexcord/ stromal ovarian tumors is not fully understood. [[Mutations]] mainly involving [[FOXL2]], [[DICER1]], [[STK11]] are involved. They are associated with [[ollier disease]] and [[Maffucci's syndrome|maffucci syndrome]].The [[microscopic]] [[pathology]] varies with the individual subtype of sexcord stromal ovarian tumors.Common [[risk factors]] in the development of sexcord/ stromal ovarian tumors include [[preterm birth]], high [[gonadotrophin]] levels, increasing [[age]] at first [[pregnancy]], [[obese]] and non-white [[women]].The [[symtoms]] of sexcord/ stromal ovarian tumors include [[Adnexal mass causes|Adnexal mass]], [[Abdominal]] & [[pelvic]] [[symptoms]], [[Bloating]], [[Urinary urgency]] or [[frequency]], [[Dysphagia]](difficulty)[[eating]]) or feeling full quickly, [[Pelvic pain|Pelvic]] or [[abdominal pain]]. Common [[complications]] of sexcord/ stromal ovarian tumors include [[malignant]] [[pleural effusion]],[[bowel obstruction]],[[ascites]]. The [[prognosis]] varies with the subtypes of [[tumor]]. Most sexcord-stromal ovarian tumors present at a low [[tumor]] [[Cancer staging|stage]] and also [[prognosis]] in these [[patients]] is excellent. [[CT]] and [[MRI]] are very helpful in the diagnosis of these tumors. [[Surgery]] and [[chemotherapy]] are the mainstay of treatment for these [[tumors]]. | |||
==Historical Perspective== | ==Historical Perspective== | ||
There is limited information about the historical perspective of sexcord/ stromal ovarian tumors | |||
==Classification== | ==Classification== | ||
| Line 13: | Line 15: | ||
==Causes== | ==Causes== | ||
The cause of sexcord/ stromal ovarian tumors has not been identified.[[Mutations]] mainly involving [[FOXL2]], [[DICER1]], [[STK11]] are involved. | |||
==Differentiating sexcord/ stromal ovarian tumors from Other Diseases== | ==Differentiating sexcord/ stromal ovarian tumors from Other Diseases== | ||
| Line 21: | Line 24: | ||
==Risk Factors== | ==Risk Factors== | ||
Common [[risk factors]] in the development of sexcord/ stromal ovarian tumors include [[preterm birth]], high [[gonadotrophin]] levels, increasing [[age]] at first [[pregnancy]], [[obese]] and non-white [[women]] | |||
==Screening== | ==Screening== | ||
There is insufficient [[evidence]] to recommend routine [[screening]] for sexcord/ stromal ovarian tumors. According to the [[US Preventive Services Task Force|US Preventive Services Task Force(USPSTF)]] , [[screening]] for sexcord/ stromal ovarian tumors is not recommended in [[asymptomatic]] [[women]] | |||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
The [[symtoms]] of sexcord/ stromal ovarian tumors include [[Adnexal mass causes|Adnexal mass]], [[Abdominal]] & [[pelvic]] [[symptoms]], [[Bloating]], [[Urinary urgency]] or [[frequency]], [[Dysphagia](difficulty)[[eating]]) or feeling full quickly, [[Pelvic pain|Pelvic]] or [[abdominal pain]]. Common complications of sexcord/ stromal ovarian tumors include [[malignant]] [[pleural effusion]],[[bowel obstruction]],[[ascites]]. The [[prognosis]] varies with the subtypes of [[tumor]]. Most sexcord-stromal ovarian tumors present at a low [[tumor]] [[Cancer staging|stage]] and also [[prognosis]] in these [[patients]] is excellent. | |||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Study of Choice=== | ===Diagnostic Study of Choice=== | ||
[[Biopsy]] is the gold standard test for the [[diagnosis]] of sexcord/ stromal ovarian tumors. There is no single [[diagnostic]] study of choice for the [[diagnosi]]s of sexcord/ stromal ovarian tumors, but these can be diagnosed based on [[CT]] and [[MRI]] findings | |||
===History and Symptoms=== | ===History and Symptoms=== | ||
The most common [[symptoms]] of sexcord/ stromal ovarian tumors include [[Adnexal mass causes|adnexal mass]], [[bloating]], [[urinary urgency]] or frequency, [[dysphagia]](difficulty [[eating]]) or feeling full quickly, [[Pelvic pain|pelvic]] or [[abdominal pain]]. Less common [[symptoms]] of sexcord/ stromal ovarian tumors include [[lymphadenopathy]], [[postmenopausal bleeding]], typical features of [[bowel obstruction]] like [[nausea]], [[vomiting]], and [[distention]]. Specific [[symptoms]] pertinent to sexcord/ stromal ovarian tumors include [[hirsutism]](excessive [[hair]]<nowiki/>growth), [[virilization]], [[menstrual]] changes like [[abnormal uterine bleeding]], [[precocious puberty]] in [[children]]. | |||
===Physical Examination=== | ===Physical Examination=== | ||
[[Patients]] with sexcord/ stromal ovarian tumors usually appear normal except few [[abdominal]] or [[pelvic]] and [[genitourinary]] findings on [[examination]]. Abdominal findings include [[Abdominal distension]], increased [[abdominal]] girth, [[abdominal tenderness]] in the right[[Left lower quadrant abdominal pain resident survival guide|/left lower abdominal quadrant]], a [[palpable]] [[abdominal mass]] in the right/left lower abdominal quadrant, [[guarding]], [[ascites]], [[hemoperitoneum]]. | |||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
[[Laboratory]] findings consistent with the [[diagnosis]] of sexcord/ stromal ovarian tumors include identifying the presence or absence of [[tumor markers]] like AMH: [[anti-Müllerian hormone]]; [[AFP]]: [[alpha-fetoprotein]]; E2: [[estradiol]]; [[hCG]]: [[human chorionic gonadotropin]]; [[LDH]]: [[lactate dehydrogenase]]; testost: [[testosterone]]; andro: [[androstenedione]]; [[Dehydroepiandrosterone|DHEA]]: dehydroepiandrostenedione; | |||
===Electrocardiogram=== | ===Electrocardiogram=== | ||
There are no [[ECG]] findings associated with the [[diagnosis]] of sexcord-stromal ovarian tumors. | |||
===X-ray=== | ===X-ray=== | ||
There are no [[x-ray]] findings associated with sexcord/ stromal ovarian tumors. | |||
===Echocardiography and Ultrasound=== | ===Echocardiography and Ultrasound=== | ||
There are no [[echocardiography]] findings associated with sexcord/ stromal ovarian tumors. [[Ultrasound]] may be helpful in the [[diagnosis]] of sexcord/ stromal ovarian tumors. Findings on an [[ultrasound]] suggestive of sexcord/ stromal ovarian tumors include [[adnexal]] hypoechoic [[Mass (medicine)|masses]] with clear border and [[Acoustic intensity|acoustic]] [[attenuation]] as well as minimal [[Doppler|doppler flow signals]]. | |||
===CT scan=== | ===CT scan=== | ||
[[Pelvic]] [[ct scan]] may be helpful in the [[diagnosis]] of sexcord/ stromal ovarian tumors. Findings on [[CT scan]] suggestive of sexcord/ stromal ovarian tumors include multicystic masses with [[solid]] components and either irregularly thickened or thin septations for both adult and juvenile [[granulosa cell tumors]], [[Fibroma]]<nowiki/>s on delayed contrast-enhanced [[computed tomography]] usually shows a [[solid]], well-defined, [[homogeneous]] [[ovarian mass]] which is isodense to the [[uterus]] with very sparse contrast uptake. Sclerosing stromal tumor will show peripheral contrast uptake, reflecting prominent [[vasculature]] in the [[cellular]] areas, with centripetal progression on late images. [[Leydig cell tumor|Leydig tumors]] tend to be small and hypoattenuating. | |||
===MRI=== | ===MRI=== | ||
[[MRI]] may be helpful in the [[diagnosis]] of sexcord/ stromal ovarian tumors. Findings on [[MRI]] suggestive of sexcord/ stromal ovarian tumors depends on the [[tumor]] subtypes. Granulosa cell tumors show [[heterogeneous]] signal intensity on both T1WI and T2WI and high signal intensity on DWI images. Fibroma, Fibrothecoma, and Thecoma appear as hypointense [[Mass (medicine)|masses]] on T1-weighted [[MRI]] with very low signal [[intensity]] on T2-weighted [[imaging]]. Sclerosing stromal tumor of ovary show hyperintense [[cystic]] components or a [[heterogeneous]] [[solid]] [[mass]] of intermediate to high signal [[intensity]] on T2-weighted [[MRI]]. | |||
===Other Imaging Findings=== | ===Other Imaging Findings=== | ||
[[PET scan|PET]]-CT may be helpful in the [[diagnosis]] of sexcord/ stromal ovarian tumors. On [[fluorodeoxyglucose]]-[[positron emission tomography]]/[[computed tomography]] [[malignant]] ovarian tumors generally have intense uptake, whereas [[tumors]] with a small [[solid]] content show decreased uptake. | |||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
There are no other [[diagnostic]]studies associated with sexcord/ stromal ovarian tumors | |||
==Treatment== | ==Treatment== | ||
===Surgery=== | ===Surgery=== | ||
[[Surgery]] is the mainstay of treatment for sexcord/ stromal ovarian tumors. The feasibility of [[surgery]] depends on the stage of the [[tumor]] at [[diagnosis]]. Both [[benign]] and [[malignant]] ovarian sex cord-stromal tumors are managed [[Surgery|surgically]]. Treatment in all [[postmenopausal]] and [[pre-menopausal]] [[women]] with [[bilateral]] involvement of [[ovaries]] includes total [[Hysterectomy|abdominal hysterectomy]] and [[bilateral]] [[salpingo-oophorectomy]] (TAH-BSO).Unilateral [[salpingo-oophorectomy]] (USO) with preservation of the [[contralateral]] [[ovary]] and the [[uterus]] is considered to be adequate [[Surgery|surgical]] treatment for the majority of [[pre-menopausal]] [[patients]] with [[granulosa cell tumors]].BEP([[bleomycin]], [[etoposide]], [[cisplatin]]) is the most accepted [[chemotherapy]] regimen even for recurrent [[disease]] that is refractory to [[hormone therapy]]. [[Hormone treatment]] is usually added for advanced [[granulosa cell tumors]](GrCTs), given their frequent [[Association (statistics)|association]] with [[oestrogen]] dependence and usually indolent course. | |||
===Primary Prevention=== | ===Primary Prevention=== | ||
There are no established measures for the [[primary prevention]] of sexcord/ stromal ovarian tumors | |||
===Secondary Prevention=== | ===Secondary Prevention=== | ||
There are no established measures for the [[secondary prevention]] of sexcord/ stromal ovarian tumors | |||
==References== | ==References== | ||
Latest revision as of 18:59, 7 May 2019
|
Sexcord/ stromal ovarian tumors Microchapters |
|
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sexcord/ stromal ovarian tumors overview On the Web |
|
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors overview |
|
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]
Overview
Ovarian sex cord-stromal tumors are a diverse group of both benign and malignant neoplasms that develop from the dividing cell population which would normally give rise to cells that surrounds the oocytes, including the cells that produce ovarian hormones (the nongerm cell and nonepithelial components of the gonads).The yearly adjusted incidence rate is approximately 2 per 1,000,000 women for sexcord-stromal ovarian tumors(SCSTs). The mortality rate has gradually been declining from1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. The age at presentation varies depending on the subtypes of sexcord-stromal ovarian tumors. Sexcord-stromal ovarian tumors(SCSTs) have more predilection in women of Caucasian background. Rates are highest among Whites, intermediate for Hispanics, and lowest among Blacks, and Asian people. Sexcord/ stromal ovarian tumors may be classified according to WHO into 3 subtypes: Pure stromal tumors, pure sexcord tumors, mixed stromal and sexcord tumors. Histological classification of sexcord-stromal ovarian tumors includes granulosa stromal cell tumors, sertoli leydig cell tumors, gynandroblastoma, and unclassified. The exact pathogenesis of sexcord/ stromal ovarian tumors is not fully understood. Mutations mainly involving FOXL2, DICER1, STK11 are involved. They are associated with ollier disease and maffucci syndrome.The microscopic pathology varies with the individual subtype of sexcord stromal ovarian tumors.Common risk factors in the development of sexcord/ stromal ovarian tumors include preterm birth, high gonadotrophin levels, increasing age at first pregnancy, obese and non-white women.The symtoms of sexcord/ stromal ovarian tumors include Adnexal mass, Abdominal & pelvic symptoms, Bloating, Urinary urgency or frequency, Dysphagia(difficulty)eating) or feeling full quickly, Pelvic or abdominal pain. Common complications of sexcord/ stromal ovarian tumors include malignant pleural effusion,bowel obstruction,ascites. The prognosis varies with the subtypes of tumor. Most sexcord-stromal ovarian tumors present at a low tumor stage and also prognosis in these patients is excellent. CT and MRI are very helpful in the diagnosis of these tumors. Surgery and chemotherapy are the mainstay of treatment for these tumors.
Historical Perspective
There is limited information about the historical perspective of sexcord/ stromal ovarian tumors
Classification
Sexcord/ stromal ovarian tumors may be classified according to WHO into 3 subtypes: Pure stromal tumors, pure sexcord tumors, mixed stromal and sexcord tumors. Histological classification of sexcord-stromal ovarian tumors includes granulosa stromal cell tumors, sertoli leydig cell tumors, gynandroblastoma, and unclassified.
Pathophysiology
The exact pathogenesis of sexcord/ stromal ovarian tumors is not fully understood. Mutations mainly involving FOXL2, DICER1, STK11 are involved. They are associated with ollier disease and maffucci syndrome.The microscopic pathology varies with the individual subtype of sexcord stromal ovarian tumors.
Causes
The cause of sexcord/ stromal ovarian tumors has not been identified.Mutations mainly involving FOXL2, DICER1, STK11 are involved.
Differentiating sexcord/ stromal ovarian tumors from Other Diseases
On the basis of age of onset, vaginal discharge, and constitutional symptoms, ovarian cancer must be differentiated from tubo-ovarian abscess, ectopic pregnancy, hydrosalpinx, salpingitis, fallopian tube carcinoma, uterine leiomyoma, choriocarcinoma, leiomyosarcoma, pregnancy, appendiceal abscess, appendiceal neoplasm, diverticular abscess, colorectal cancer, pelvic kidney, advanced bladder cancer, and retroperitoneal sarcoma.
Epidemiology and Demographics
The yearly adjusted incidence rate is approximately 2 per 1,000,000 women for sexcord-stromal ovarian tumors(SCSTs). The mortality rate has gradually been declining from1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. The age at presentation varies depending on the subtypes of sexcord-stromal ovarian tumors. Sexcord-stromal ovarian tumors(SCSTs) have more predilection in women of Caucasian background. Rates are highest among Whites, intermediate for Hispanics, and lowest among Blacks, and Asian people. Intrestingly there has been increases in incidence and mortality rates in less developed countries with recent economic growth and lifestyle changes.
Risk Factors
Common risk factors in the development of sexcord/ stromal ovarian tumors include preterm birth, high gonadotrophin levels, increasing age at first pregnancy, obese and non-white women
Screening
There is insufficient evidence to recommend routine screening for sexcord/ stromal ovarian tumors. According to the US Preventive Services Task Force(USPSTF) , screening for sexcord/ stromal ovarian tumors is not recommended in asymptomatic women
Natural History, Complications, and Prognosis
The symtoms of sexcord/ stromal ovarian tumors include Adnexal mass, Abdominal & pelvic symptoms, Bloating, Urinary urgency or frequency, [[Dysphagia](difficulty)eating) or feeling full quickly, Pelvic or abdominal pain. Common complications of sexcord/ stromal ovarian tumors include malignant pleural effusion,bowel obstruction,ascites. The prognosis varies with the subtypes of tumor. Most sexcord-stromal ovarian tumors present at a low tumor stage and also prognosis in these patients is excellent.
Diagnosis
Diagnostic Study of Choice
Biopsy is the gold standard test for the diagnosis of sexcord/ stromal ovarian tumors. There is no single diagnostic study of choice for the diagnosis of sexcord/ stromal ovarian tumors, but these can be diagnosed based on CT and MRI findings
History and Symptoms
The most common symptoms of sexcord/ stromal ovarian tumors include adnexal mass, bloating, urinary urgency or frequency, dysphagia(difficulty eating) or feeling full quickly, pelvic or abdominal pain. Less common symptoms of sexcord/ stromal ovarian tumors include lymphadenopathy, postmenopausal bleeding, typical features of bowel obstruction like nausea, vomiting, and distention. Specific symptoms pertinent to sexcord/ stromal ovarian tumors include hirsutism(excessive hairgrowth), virilization, menstrual changes like abnormal uterine bleeding, precocious puberty in children.
Physical Examination
Patients with sexcord/ stromal ovarian tumors usually appear normal except few abdominal or pelvic and genitourinary findings on examination. Abdominal findings include Abdominal distension, increased abdominal girth, abdominal tenderness in the right/left lower abdominal quadrant, a palpable abdominal mass in the right/left lower abdominal quadrant, guarding, ascites, hemoperitoneum.
Laboratory Findings
Laboratory findings consistent with the diagnosis of sexcord/ stromal ovarian tumors include identifying the presence or absence of tumor markers like AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione;
Electrocardiogram
There are no ECG findings associated with the diagnosis of sexcord-stromal ovarian tumors.
X-ray
There are no x-ray findings associated with sexcord/ stromal ovarian tumors.
Echocardiography and Ultrasound
There are no echocardiography findings associated with sexcord/ stromal ovarian tumors. Ultrasound may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. Findings on an ultrasound suggestive of sexcord/ stromal ovarian tumors include adnexal hypoechoic masses with clear border and acoustic attenuation as well as minimal doppler flow signals.
CT scan
Pelvic ct scan may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. Findings on CT scan suggestive of sexcord/ stromal ovarian tumors include multicystic masses with solid components and either irregularly thickened or thin septations for both adult and juvenile granulosa cell tumors, Fibromas on delayed contrast-enhanced computed tomography usually shows a solid, well-defined, homogeneous ovarian mass which is isodense to the uterus with very sparse contrast uptake. Sclerosing stromal tumor will show peripheral contrast uptake, reflecting prominent vasculature in the cellular areas, with centripetal progression on late images. Leydig tumors tend to be small and hypoattenuating.
MRI
MRI may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. Findings on MRI suggestive of sexcord/ stromal ovarian tumors depends on the tumor subtypes. Granulosa cell tumors show heterogeneous signal intensity on both T1WI and T2WI and high signal intensity on DWI images. Fibroma, Fibrothecoma, and Thecoma appear as hypointense masses on T1-weighted MRI with very low signal intensity on T2-weighted imaging. Sclerosing stromal tumor of ovary show hyperintense cystic components or a heterogeneous solid mass of intermediate to high signal intensity on T2-weighted MRI.
Other Imaging Findings
PET-CT may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. On fluorodeoxyglucose-positron emission tomography/computed tomography malignant ovarian tumors generally have intense uptake, whereas tumors with a small solid content show decreased uptake.
Other Diagnostic Studies
There are no other diagnosticstudies associated with sexcord/ stromal ovarian tumors
Treatment
Surgery
Surgery is the mainstay of treatment for sexcord/ stromal ovarian tumors. The feasibility of surgery depends on the stage of the tumor at diagnosis. Both benign and malignant ovarian sex cord-stromal tumors are managed surgically. Treatment in all postmenopausal and pre-menopausal women with bilateral involvement of ovaries includes total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO).Unilateral salpingo-oophorectomy (USO) with preservation of the contralateral ovary and the uterus is considered to be adequate surgical treatment for the majority of pre-menopausal patients with granulosa cell tumors.BEP(bleomycin, etoposide, cisplatin) is the most accepted chemotherapy regimen even for recurrent disease that is refractory to hormone therapy. Hormone treatment is usually added for advanced granulosa cell tumors(GrCTs), given their frequent association with oestrogen dependence and usually indolent course.
Primary Prevention
There are no established measures for the primary prevention of sexcord/ stromal ovarian tumors
Secondary Prevention
There are no established measures for the secondary prevention of sexcord/ stromal ovarian tumors